Bcl-2 family member Bcl-G is not a proapoptotic protein

M Giam1,2, T Okamoto1,2,3, JD Mintern1,2,4, A Strasser1,2 and P Bouillet1,2

The three major subgroups of the Bcl-2 family, including the prosurvival Bcl-2-like proteins, the proapoptotic Bcl-2 homology (BH)3-only proteins and Bax/Bak proteins, regulate the mitochondrial apoptotic pathway. In addition, some outliers within the Bcl-2 family do not fit into these subgroups. One of them, Bcl-G, has a BH2 and a BH3 region, and was proposed to trigger apoptosis. To investigate the physiological role of Bcl-G, we have inactivated the gene in the mouse and generated monoclonal antibodies to determine its expression. Although two isoforms of Bcl-G exist in human, only one is found in mice. mBcl-G is expressed in a range of epithelial as well as in dendritic cells. Loss of Bcl-G did not appear to affect any of these cell types. mBcl-G only binds weakly to prosurvival members of the Bcl-2 family, and in a manner that is independent of its BH3 domain. To understand what the physiological role of Bcl-G might be, we searched for Bcl-G-binding partners through immunoprecipitation/mass spectroscopy and yeast-two-hybrid screening. Although we did not uncover any Bcl-2 family member in these screens, we found that Bcl-G interacts specifically with proteins of the transport particle protein complex. We conclude that Bcl-G most probably does not function in the classical stress-induced apoptosis pathway, but rather has a role in protein trafficking inside the cell.

Received 25.7.12; accepted 25.7.12; Edited by G Melino

Keywords: apoptosis; Bcl-G; Bcl-2 family

Abbreviations: BH, Bcl-2 homology domain; cDC, conventional dendritic cell; pDC, plasmacytoid dendritic cell; HA, haemagglutinin; mAb, monoclonal antibody; DMEM, Dulbecco’s modified Eagle’s medium; Y2H, yeast two-hybrid; TRAPP, transport particle protein

Citation: Cell Death and Disease (2012) 3, e404; doi:10.1038/cddis.2012.130; published online 11 October 2012

Subject Category: Cancer

Proteins of the Bcl-2 family are divided into three subgroups according to their function and the presence of characteristic Bcl-2 homology (BH) domains. The prosurvival members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1/Bfl-1) contain four BH domains and are critical for cell survival. The proapoptotic proteins Bax and Bak, which also contain all four BH domains and are structurally similar to their prosurvival relatives, are essential for mitochondrial outer membrane permeabilisation. The BH3-only proteins (Bim, Bid, Puma, Bmf, Bik, Bad, Noxa and Hrk) are essential initiators of apoptosis that cause activation of Bax and Bak, either directly or indirectly by binding to and blocking the prosurvival Bcl-2 family members. The presence of the BH1, BH2 and BH3 domains in the multi-domain proteins determines their three-dimensional structure, in particular the existence on their surface of a groove that functions as a receptor for the BH3 domain of BH3-only or the Bax/Bak proteins. Mutations in the conserved residues of the BH3 domain of prosurvival proteins almost invariably modify or abrogate their interaction with the groove of the prosurvival Bcl-2-like proteins.

A number of other proteins harbouring a BH3-like domain (and sometimes another BH domain) have been described. Although many of these proteins have been included in the Bcl-2 family, their role in stress-induced apoptosis is often controversial, and some of these proteins have even been implicated in diverse non-apoptotic cellular functions, such as cell cycle regulation, DNA repair, ubiquitination, metabolism or autophagy.

BCL-G, also known as BCL2L14, was first described as a novel proapoptotic member of the Bcl-2 family. The human BCL-G gene encodes two major isoforms, BCL-GL and BCL-GS. BCL-GL contains both BH3 and BH2 domains, whereas BCL-GS contains only the BH3 domain. BCL-G was reported to kill cells by binding and neutralisation of prosurvival BCL-XL. In contrast, BCL-GL did not bind BCL-XL and showed only poor killing activity. Mouse Bcl-G is 68% identical and 78% similar to human BCL-G. Functional characterisation of mBcl-G has been limited, and most studies have considered its proapoptotic nature as a fait accompli.

To characterise this unusual member of the Bcl-2 family, we have generated highly specific monoclonal antibodies (mAb) and Bcl-G-deficient mice. Our results highlight differences between the mouse and human Bcl-G genes and suggest that Bcl-G may not function as a classical BH3-only protein.
Results

Generation of Bcl-G-deficient mice. Targeting of the mouse Bcl-G gene in embryonic stem (ES) cells was achieved by introducing loxP sites flanking the ATG-containing exon 3 (Figure 1a). Hygromycin-resistant Bruce 4 clones were isolated and their genomic DNA analysed by Southern blotting (Figure 1b). Bcl-G gene-targeted mice were established and maintained on an inbred C57BL/6 genetic background, and were genotyped by PCR (Figure 1c). Bcl-G<sup>−/−</sup> mice were born at the expected Mendelian frequency from intercross matings of Bcl-G<sup>+/−</sup> mice (Figure 1d). The general appearance and behaviour of these mice was normal and they were indistinguishable from their wild-type (WT) littermates.

As expected, no RNA could be detected by RT-PCR in tissues from Bcl-G<sup>−/−</sup> mice (Figure 2a). Our mAb (clone 2E11) detected a 38-kDa band in WT testis, and this band was absent from Bcl-G<sup>−/−</sup> testis (Figure 2b). Interestingly, only one Bcl-G isoform is produced from the mouse Bcl-G gene, whereas a long (BCL-G<sub>L</sub>) and a short (BCL-G<sub>S</sub>) isoform are produced from human BCL-GL. In the testis, Bcl-G immunoreactivity was limited to the late-stage spermatids within the seminiferous tubules (Figure 2c). No staining was seen in the mature sperm found in the epididymal tubules (data not shown). Interestingly, Bcl-G-deficient males and females exhibited normal reproductive behaviour and produced litters of normal size.

Bcl-G is expressed in diverse mouse tissues but is not required for their development and function. In addition to the male reproductive organs, high levels of mBcl-G were also found in the thymus, small intestine and colon. Intermediate expression levels were seen in pancreas, spleen and lung, whereas little or no Bcl-G expression was observed in the brain, kidney and liver (Figure 3a). Mouse Bcl-G protein is most similar to human BCL-GL, and its expression closely matches what is known for hBCL-GL mRNA. Bcl-G expression was high in many epithelial cells, in particular those lining the gastrointestinal tract and the lumen of mammary ducts (Figure 3b and data not shown). However, no obvious defects were found in these organs in Bcl-G<sup>−/−</sup> mice. Bcl-G<sup>−/−</sup> intestines had similar lengths of villi and crypt depths as those from WT mice (Figure 3b). The numbers of Paneth and goblet cells were also normal, indicating that Bcl-G is not required for intestinal epithelial differentiation (data not shown). In the mammary gland, Bcl-G loss did not affect ductal morphogenesis, and the lumens of ducts in Bcl-G<sup>−/−</sup> females were clear and well developed (Figure 3b). As the survival and growth of pups from litters of Bcl-G<sup>−/−</sup> females was no different from those of WT mothers, we conclude that Bcl-G deficiency did not significantly affect mammary development during pregnancy, nor did it affect milk production or nursing behaviour (data not shown).

Bcl-G is expressed by dendritic cells. Bcl-G was expressed in large cells within the thymic medulla and the centre of lymphocytic follicles of the spleen and lymph nodes (Figure 3b, and data not shown). No significant Bcl-G staining was detected in lymphocytes. The Immunological Genome Project gene expression database revealed high expression of Bcl-G mRNA in CD8<sup>+</sup> dendritic cells (DCs). We examined Bcl-G expression in select DC subsets from WT spleen using our Bcl-G-specific antibodies (Figure 3c). In accordance with the mRNA expression results, conventional DCs (cDCs; CD11c<sup>hi</sup> CD45RA<sup>−</sup>) had significantly higher levels of Bcl-G than plasmacytoid DCs (pDCs; CD11c<sup>int</sup> CD45RA<sup>+</sup>) (Figure 3c). This high expression was largely contributed by the CD8<sup>+</sup> cDC subset, although Bcl-G was also present at lower levels in the CD4<sup>+</sup> and double negative cDC subsets (Figure 3c). Bcl-G expression was increased in splenic cDCs upon stimulation with CpG oligonucleotides, perhaps indicating a role for Bcl-G in the Toll-like receptor 9 signalling pathway (Figure 3c).

The thymic medulla contains epithelial cells that are present in close proximity to the thymic DCs. As Bcl-G displayed expression in certain epithelial cell types in other organs, we investigated whether it is present in medullary thymic epithelial cells. However, double immunofluorescence staining for Bcl-G and the medullary thymic epithelial cell marker keratin-5 on WT thymus sections did not show any colocalisation, demonstrating that the DCs must constitute the majority of the Bcl-G-expressing cells in the thymus (Supplementary Figure 1).

Bcl-G<sup>−/−</sup> mice have normal haematopoietic cell subset composition. To investigate the impact of Bcl-G loss on the haematopoietic compartment, we analysed the cellular composition of blood, thymus and spleen in adult Bcl-G-deficient mice (Figures 4a–c). Overall numbers of red blood cells, white blood cells and platelets were all normal in Bcl-G-deficient mice (Figure 4a and data not shown). Similarly, thymi and spleens of Bcl-G<sup>−/−</sup> mice had similar weights and total cellularities as those of WT mice (Supplementary Figure 2, and Figures 4b and c). Bcl-G<sup>−/−</sup> mice also had normal numbers of each of the major thymic and splenic subpopulations analysed, showing that loss of Bcl-G did not affect the development and homeostasis of the mouse haematopoietic system (Figures 4b and c).

Bcl-G is dispensable for splenic DC development and apoptosis. As Bcl-G is highly expressed in DCs, particularly the CD8<sup>+</sup> subtype, we next measured the numbers of the various splenic DC subsets in Bcl-G<sup>−/−</sup> mice using flow cytometry (Figure 4d and Supplementary Figure 3). The numbers of Bcl-G<sup>−/−</sup> DCs were comparable to those in WT mice (Figure 4d and Supplementary Figure 3). Because of the higher expression of Bcl-G in CD8<sup>+</sup> DCs relative to other DC subsets, we also examined the function of the Bcl-G<sup>−/−</sup> CD8<sup>+</sup> DCs, using several antigen cross-presentation assays (Supplementary Figure 4). However, neither the in vivo cross-presentation assay nor the CTL killing assay revealed any difference between the WT and Bcl-G-deficient DCs, indicating that Bcl-G may not be required for cross-presentation and naive T-cell activation (Supplementary Figure 4).

We next compared the survival of Bcl-G<sup>−/−</sup> and WT DCs in culture (Figure 4e). Splenic DCs from the three subsets (pDC, CD8<sup>+</sup> and CD8<sup>−</sup> cDC) were purified by FACS and placed in
medium with or without the survival factor granulocyte-macrophage colony-stimulating factor (GM-CSF; 10 ng/ml). Consistent with previous reports, 7,8 WT DCs, particularly the pDC subtype, underwent rapid cell death in vitro, with only 20% pDCs surviving after 24 h in culture (Figure 4e). There was no significant difference in the rate of death of Bcl-G0/0 DCs from any of the three subtypes when compared with their WT counterparts (Figure 4e). These results demonstrate that Bcl-G is not required for spontaneous DC apoptosis, both in the presence or absence of GM-CSF. Transient overexpression of mouse Bcl-G did not cause significant killing of 293T cells (Supplementary Figure 5A), further indicating that mBcl-G lacks significant pro-apoptotic activity.

Bcl-G does not bind strongly to the prosurvival Bcl-2-like proteins. The complex interactions between three major subgroups of the Bcl-2 family determine whether apoptosis is activated or not. 9,10 Human BCL-G S was reported to bind BCL-X L through its BH3 domain, whereas the presence of the additional BH2 domain in hBCL-G L was suggested to prevent its binding to BCL-X L.4 As mBcl-G is most similar to hBCL-G L, and as we could not find any evidence that mBcl-G exerted significant proapoptotic activity, we investigated whether it could even bind to the antiapoptotic Bcl-2 family members or Bax/Bak. Haemagglutinin (HA)-tagged mBcl-G was transiently overexpressed together with Flag-tagged prosurvival proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1), Flag-Bax, Flag-Bak or empty vector as a negative control (Figure 5a). Bcl-G could bind weakly to all
five prosurvival Bcl-2 family members when they were overexpressed (Figure 5a and Supplementary Figure 5B). In contrast, there was no evidence for significant interaction between mBcl-G and Bax or Bak (Figure 5a).

To determine the role of the BH3 domain in this weak binding, we generated several mutants of mBcl-G, including one lacking the entire BH3 domain (D_BH3), one in which the conserved leucine within the BH3 domain was changed to alanine (L217A) and one which had the conserved glutamine and aspartate residues mutated to alanine (Figure 5b).

Unexpectedly, these mutant Bcl-G proteins retained the ability to interact weakly with Bcl-xL and all four other prosurvival proteins (Figure 5b and data not shown). These results indicate that Bcl-G might not bind to the prosurvival Bcl-2 family members in the same manner as the canonical BH3-only proteins, such as Bim or Puma. Indeed, replacement of the BH3 domain of Bcl with that of Bcl-G also resulted in complete loss of Bim’s killing potential when overexpressed in 293T cells (Supplementary Figure 5A).

Finally, we were unable to observe any endogenous binding of Bcl-G to Bcl-xL, Bcl-2 and Mcl-1 in mouse tissue (testis, thymus or spleen) protein lysates when we immunoprecipitated either Bcl-G or Bcl-xL (Supplementary Figure 6). Collectively, these observations suggest that Bcl-G might not function as a classical BH3-only protein.

Novel potential interacting partners for Bcl-G. We then conducted a proteomic screen to identify potential new interacting partners for Bcl-G and thus gain clues on a possible alternative function. The strategy is depicted in Figure 6. Whole-cell lysates were prepared from intestinal epithelial cells (IECs) isolated from WT or Bcl-G-/- mice. The presence of Bcl-G in the lysates from the WT cells but not in those from the control (Bcl-G-/-) cells was verified by

![Figure 3](image-url)
western blotting (Supplementary Figure 7). Bcl-G protein complexes were immunoprecipitated from these protein lysates using two different Bcl-G-specific mAbs, 2E11 and 10C9, that recognise different epitopes within the Bcl-G protein (Figure 6). Immunoprecipitates were analysed by mass spectrometry. A total of 327 unique proteins were identified in this screen (Figure 6). Of these, 216 proteins could be eliminated...
as non-specific interactors, as they were found in all the samples, including immunoprecipitates from Bcl-G/−/− cells. As expected from the western blots, Bcl-G-derived peptides were only found in the WT samples (Supplementary Figure 8). A total of 110 unique proteins that potentially interact with Bcl-G were identified (Figure 6 and Supplementary Figure 9). Of these, 19 proteins were found in immunoprecipitates with both antibodies (Figure 6 and Supplementary Figure 9D). Notably, none of the Bcl-2 family members were identified in this screen, consistent with our overexpression/co-immunoprecipitation studies (Figure 5).

Yeast two-hybrid screening identifies Trappc6b as a Bcl-G-binding protein. We reasoned that an independent approach would help to validate and strengthen the results of the IP–MS experiment. We therefore used full-length Bcl-G as a bait to perform a yeast two-hybrid (Y2H) screening of a normalised mouse universal cDNA library (Clontech, Mountain View, CA, USA). In a screen of approximately 3 × 10^6 transformants, we obtained 52 colonies growing on plates containing selective medium. Of the cDNAs picked up in this screen, three were in the correct reading frame. cDNAs encoding the transport particle protein (TRAPP) complex 6b (Trappc6b) represented 19 of the 52 isolated clones. The other clones encoded parts of Sorting nexin 14 (Snx14) and Transmembrane protein 167B (Tmem167B) and were each found once. Importantly, none of the Bcl-2 family members were pulled down as potential Bcl-G-binding partners in this screen. In addition, mBcl-G did
not appear to bind to itself when overexpressed, in contrast to a previous report.12

Out of the three potential hits, we focused our attention on Trappc6b, as three components of TRAPP complexes (Trappc3, Trappc4 and Trappc5) had been identified in the IP–MS experiment (Table 1). To confirm the Y2H screening results, we introduced the pGADT7–Trappc6b plasmid into the AH109 yeast strain together with bait plasmid pGBT9–Bcl-G (FL) or pGBT9 vector alone (V; Figure 7a). Only yeast cells transformed with both Trappc6b and Bcl-G survived on -Leu-Trp-His-Ade plates and turned blue in the X-gal assay that detects the presence of β-galactosidase activity (Figure 7a). This interaction was specific, as deleting particular regions (amino acids 103–136 and 273–328) of the Bcl-G protein resulted in lack of β-galactosidase activity and no growth on the selective plates (Figure 7a and Supplementary Figure 10).

In a pull-down experiment, ectopically expressed Flag–Trappc6b was found to bind to His-tagged Bcl-G, immobilised on Ni-NTA agarose beads (Figure 7b).

Collectively, the results from the Y2H screen and the IP–MS experiment confirm that Bcl-G does not bind significantly to other members of the Bcl-2 family and strongly suggest that it is involved in vesicle trafficking and protein transport across the cells by interacting with the TRAPP complex.

Table 1: Trapp complex subunits identified as potential mouse Bcl-G-binding partners in the IP–MS proteomic screen

| Acc. no. | Gene symbol | Protein name | No of peptides | % Coverage |
|----------|-------------|--------------|----------------|------------|
| Q9ES56   | Trappc4     | Trafficking protein particle complex subunit 4 | 2              | 11.00      |
| Q9CQA1   | Trappc5     | Trafficking protein particle complex subunit 5 | 2              | 9.57       |
| O55013   | Trappc3     | Trafficking protein particle complex subunit 3 | 2              | 12.80      |

Discussion

Proteins of the Bcl-2 family are characterised by the presence of BH domains that are important in determining the three-dimensional structure of these proteins and their interactions with the other members of the family. In this regard, mBcl-G and its human homologue BCL-G(L) are rather unique members of the Bcl-2 family, as they contain both BH3 and BH2 domains.4,5 The only other protein in this family to contain such a combination of BH domains is Bfk.13 Overexpression of hBCL-Gs was found to induce apoptosis in certain cell lines, whereas hBCL-G(L) did not.4 Accordingly, BCL-G is widely (if not universally) considered to encode yet another proapoptotic BH3-only protein, but this proapoptotic activity has not been confirmed in an independent study, let alone within a physiological context. A database search indicated that the BCL-Gs isoform only exists in humans, as the alternative splice acceptor site that is used to produce it is not conserved in other species. In accord with its lack of killing activity (even when overexpressed), hBCL-G(L) did not bind BCL-XL.4 Although we detected a weak interaction of mBcl-G with several prosurvival Bcl-2 family members, this interaction was still observed when the BH3 domain of Bcl-G with several prosurvival Bcl-2 family members, this interaction was still observed when the BH3 domain of Bcl-G was mutated or removed. In fact, closer examination indicates that the BH3 domain of Bcl-G is involved in vesicle trafficking and protein transport across the cells by interacting with the TRAPP complex.

![Figure 7](image-url)
domain of Bcl-G does not conform to the BH3 consensus sequence; for example, the uniformly hydrophobic residue in position 9/3 is replaced with a serine (S220). This may explain why mBcl-G binds poorly to prosurvival family members. Strikingly, no Bcl-2 family member, prosurvival or proapoptotic, was pulled down in either our proteomic screen or the Y2H screen. Collectively, these results indicate that mBcl-G is most likely not involved in interactions with other Bcl-2 family members and, therefore, probably does not function in the intrinsic apoptotic pathway.

To determine which tissues and cell types normally express Bcl-G, we have generated three highly specific mAbs.14 In western blots, mBcl-G appears as a ~38-kDa band that is not present in Bcl-G−/− animals. It is worth noting that some of the earliest commercially available anti-BCL-G antibodies detect a single ~22-kDa band that corresponds neither to the size of hBCL-Gn nor that of hBCL-Gs. We found that Bcl-G is highly expressed in many epithelial cells, as well as in DCs. This guided the choice of the source of protein lysates for our IP–MS experiment, as we wanted to avoid using Bcl-G overexpression. Our search for novel interacting partners using two independent approaches led to the discovery that Bcl-G may be a component of the TRAPP complex, which is involved in vesicle-mediated protein transport. Two large multi-subunit TRAPP complexes have been identified in yeast, whereas there seems to be only one TRAPP complex in mammals.15 These complexes function in the endoplasmic reticulum (ER) to Golgi transport, as well as intra-Golgi transport. Our immunofluorescence studies did not reveal any specific subcellular localisation of Bcl-G in the Golgi, ER or within vesicular structures when overexpressed in HeLa cells.14 However, Bcl-G overexpressed in HeLa cells may not reflect its physiological localisation as it was shown in the case of Trapp complex subunit 3.16 As Bcl-G does not exist in yeast, it is difficult to predict what its precise function in the TRAPP complex is, and more work is required to determine this function.

The BCL-G gene is located on human chromosome region 12p12–13, which has been associated with a range of malignancies.17 A search for a putative prostate cancer tumour suppressor gene within this region revealed that Bcl-G transcript levels were downregulated in tumour samples compared with normal prostate tissue.18 No mutations or expression changes of the Bcl-G gene were found in children with acute lymphoblastic leukaemia,17 but a TEL–AML1 fusion transcript involving BCL-G was reported in another.19 In breast cancer, Bcl-G expression was found to be abnormally reduced and possibly regulated post-translationally by maternal embryonic leucine zipper kinase, a recently identified protein kinase and candidate oncoprotein upregulated in several types of cancer.20 In all these studies, BCL-G was considered a proapoptotic BH3-only protein and, as such, a potential tumour suppressor. These considerations must now be revised in the light of our results, which show that Bcl-G is not an inducer of apoptosis, although they do not preclude by any means that BCL-G may still work as a tumour suppressor. Hence, the importance of Bcl-G in initiation and progression of cancer remains to be studied.

Certain cell types with prominent Bcl-G expression were studied in detail in an attempt to identify a defect caused by the loss of this protein. Most DCs have a short lifespan, and upon activation and antigen presentation, they rapidly undergo apoptosis to limit the potency of the immune response that had been elicited.8,21 Members of the Bcl-2 protein family have critical roles in DC apoptosis.21–23 For example, DCs from Bim−/− mice are abnormally resistant to spontaneous apoptosis, leading to enhanced T-cell activation and autoimmune-body production in vivo.7,24 In contrast, loss of Bcl-G did not impact on DC lifespan, nor did it significantly impact on their main functions, such as antigen cross presentation.

The lack of an obvious phenotype in Bcl-G-deficient mice could be attributed to the existence of functional redundancy, as was reported for other members of the Bcl-2 protein family.25 However, our results have indicated that Bcl-G might not have a proapoptotic function after all. It thus seems reasonable to investigate the function of Bcl-G further before embarking on time-consuming and costly double-knockout studies.

Several BH3 domain-containing proteins have been shown to function outside the conventional Bcl-2-regulated apoptotic pathway, including cell cycle control, autophagy, calcium homeostasis and ER morphogenesis.26 It appears likely that Bcl-G may have to be added to this list. The Bcl-G-deficient mice as well as the mAbs that we have generated should prove valuable tools to further study this intriguing Bcl-2 family member.

Materials and Methods

Generation of Bcl-G−/− mice. The targeting construct was designed to introduce loxP sites on either side of the ATG start codon containing exon 3, as well as an FRT-flanked PGK-hygromycin resistance cassette for screening purposes. The targeting construct was electroporated into C57BL/6-derived Bruce 4 ES cells.26 Homologous recombination events were identified by Southern blotting, using external 5′- and 3′-genomic probes, and blotting with a hygromycin-specific probe confirmed single-construct integration. Two correctly targeted ES cell clones were injected into blastocysts, resulting in two independent Bcl-G−/− targeted mouse strains. Exon 3 and the hygromycin-resistance cassette were deleted by crossing the resultant Bcl-GloxP/loxP heterozygous mice with C57BL/6 cre deleter mice, and the Cre transgene was subsequently eliminated by crossing offspring to C57BL/6 mice. All of the mice analysed were devoid of hygro and cre. Genotyping of Bcl-G-deficient mice was performed using a three-primer PCR reaction using a common forward primer (5′-TGGCTTCCTCCATTATAACCC-3′), together with two reverse primers (5′-CTGGAACGACAGAGGGCAAA-3′ and 5′-TATTACATCAAGAGCCGACAA-3′). The WT and mutant alleles produced products of 202 and 346 bp, respectively.

C57BL/6, B6.CH-2 bm1 (lmt) and OT-2 mt mice were obtained from WEHI Bioservices (Kew, VIC, Australia). All animal procedures were reviewed and approved by the Melbourne Directorate Animal Ethics Committee.

RT-PCR analysis. RNA extraction was performed with the TRIzol method (Life Technologies, Mulgrave, VIC, Australia) according to the manufacturer’s instructions. cDNA was synthesised using the TaqMan Gold RT-PCR kit (Life Technologies). The PCR amplification step used GoTag Green Master Mix (Promega, Alexandria, NSW, Australia) and 25 pmol of each forward (5′-CCCCAGCTCTCCAGAAGCAAG-3′) and reverse (5′-CAGCAAGCTCAACATTGC-3′) primers.

Western blotting and immunoprecipitation. HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, transiently transfected using FuGene 6 reagent (Roche, Dee Why, NSW, Australia), and were harvested 40 h post-transfection. Cells were lysed in 20 mM Tris-ph 7.4, 135 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol and 1% Triton X-100 supplemented with complete protease inhibitor cocktail tablets (Roche). Lysates were incubated with protein G-sepharose beads and antibodies against HA (3F10; Roche), Flag (M2; Sigma-Aldrich, Rowville, VIC, Australia), and Acidine Yellow (Promega, Alexandria, NSW, Australia) and subjected to immunoprecipitation.
VIC, Australia) or EE (Glu-Glu; Covance, North Ryde, NSW, Australia). Protein complexes were resolved on 4–12% Bis-Tris SDS-PAGE gels (Life Technologies) and detected on western blots with rat mAbs to Bcl-G (E211) or HA and mouse mAbs to Flag (M2, Sigma-Aldrich), HSPT0 (NE; a kind gift from Dr R Anderson, Peter MacCallum Cancer Research Centre, Melbourne, VIC, Australia) or Actin (AC-40; Sigma-Aldrich). Labelled protein bands were detected by incubation with goat anti-mouse Ig or goat anti-rat Ig antibodies conjugated to horseradish peroxidase (Southern Biotech, Birmingham, AL, USA), followed by chemiluminescence analysis (ECL/GE Healthcare, Rydalmere, NSW, Australia)

**Histology and tissue immunohistochemistry.** Mouse tissues were fixed in 10% formalin. Protocols used for immunohistochemistry and immunofluorescence have been described.14

**Immunofluorescence and flow cytometric analysis.** Peripheral blood was analysed with the ADVIA 120 Hematology System (Bayer, Tarrytown, NY, USA). Single-cell suspensions prepared from thymi and spleens were counted using the CASY Cell Counter (Roche), concentrated, and stained for flow cytometric analysis using fluorochrome (fluorescein isothiocyanate, PE, APC or PerCP)- conjugated antibodies to Thyl.2 (T24.31.2), CD8 (YTS169), B220 (RA3-6B2), IgM (5.1), IgD (1126C), Gr-1 (8C5), CD3 (KT3-11), CD4 (YTA-321), CD11b (Mac-1) and Ter-119 (erythroid cell marker). Staining with propidium iodide (5 μg/ml) was used to label dead cells. Data were acquired on either a FACScan or an LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). All data analysis was performed using FlowJo software (TreeStar, Ashland, OR, USA).

**DC isolation and treatments.** DCs were isolated from spleens of mice according to previously published protocols,28 followed in some cases by high-speed cell sorting (MoFlo, Cytomation, Fort Collins, CO, USA). DC populations purified from WT or Bcl-G−/− mice were added to 96-well plates at 1 × 105 cells per well in RPMI medium 1640 supplemented with 10% FCS, 50 μM 2-mercaptoethanol, 2 mM l-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin with or without supplementation with 100 ng/ml GM-CSF (PeproTech, Rocky Hill, NJ, USA) and/or 0.5 μM CpG1168 (Geneworks, Hindmarsh SA, Australia). In vivo OT-1 TCR transgenic T-cell proliferation assays and in vivo CTL assays were performed as described.29

**Isolation of primary small IECs.** Small intestines from either WT or Bcl-G−/− mice were removed, opened longitudinally, cut into 0.5-cm pieces and placed into ice-cold DMEM media containing 1 mM DTT. Gut pieces were shaken gently for 15 min at 37 C. The dislodged cells filtered out and solid material placed in PBS solution containing 15 mM EDTA, followed by a further 10-min incubation with shaking at 37 C. After vortexing to dislodge IECs, cell suspensions were passed through cell strainers (100 μm, BD Biosciences) and centrifuged at 4 C at 300 × g for 5 min.

**Mass spectrometry.** Immunoprecipitates were resolved on a 4–12% Bis-Tris SDS-PAGE gel (Invitrogen, Grand Island, NY, USA) and visualised by staining with the Colloidal Blue Staining Kit (Invitrogen). The gel regions between 25–55 kDa were excised and divided into eight equal slices, which were then subjected to in-gel reduction, alkylidy and tryptic digestion. Extracted peptides were injected and fractionated by nanoflow reverse-phase liquid chromatography on a nano LC system (1200 series; Agilent, Santa Clara, CA, USA). The nano HPLC was coupled online to an LTQ Orbitrap mass spectrometer equipped with a nanoelectrospray ion source (Thermo Fisher Scientific, Scoresby, VIC, Australia) and/or 0.5 μM CpG1168 (Geneworks, Hindmarsh SA, Australia). In vivo OT-1 TCR transgenic T-cell proliferation assays and in vivo CTL assays were performed as described.29

**Ni–NTA agarose purification.** Forty-eight hours post-transfection, 293T cells were washed with PBS and resuspended in onxy lysis buffer. Ni–NTA agarose beads (20 μl Qiagen, Chatswood, VIC, Australia) pre-incubated for 1 h with recombinant His-Bcl-G protein (12 μg) were washed, added to cell extracts and rotated at 4 C for 2 h. Precipitates were washed four times with lysis buffer and then boiled in 40 μl 2 × NuPAGE LDS buffer (Invitrogen) followed by SDS-PAGE analysis.

**Data analysis.** All graphing and statistical analyses were performed using the Prism v4.0 (GraphPad Software, San Diego, CA, USA).

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements.** We thank M Robati for technical assistance; LA O’Reilly for sharing reagents and expertise; G Siciliano, J Coughlin, E Sutherland and S O’Connor for mouse care; J Corbin for automated blood analysis; B Helbert and C Young for genotyping; K Wycherley for mAb production; E Tsui, S Mihajlovic and S O’Connor for mouse care; J Corbin for automated blood analysis; B Helbert and C Young for genotyping; K Wycherley for mAb production; E Tsui, S Mihajlovic and H Patisouaras and E Kapp from the Joint Proteomics Laboratory for mass spectrometry analysis. This work was supported by the Australian NHMRC (Program Grant 461221, Independent Research Institutes Infrastructure Support Scheme Grant 361646, and a Career Development Award), the Leukemia and Lymphoma Society (Specialised Center of Research Grant 7015), and infrastructure support from the NHMRC (IRISS) and the Victorian State Government (OIS). M Giam was funded by University of Melbourne under the Endeavour IPRS scholarship programme. JD Mintern is the recipient of an NHMRC Career Development Award.

1. Giam M, Huang DC, Boullot P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27: S128–S136.
2. Hinds MG, Day CL. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol 2005; 15: 690–699.
3. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. J Biol Chem 2007; 282: 2760–2765.
4. Nakamura M, Tanigawa Y. Characterization of ubiquitin-like polypeptide acceptor protein, a novel pro-apoptotic member of the Bcl-2 family. Eur J Biochem 2003; 270: 4052–4058.
5. Heng TS, Painter MW. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 2008; 9: 1091–1094.
6. Chen M, Huang L, Wang J. Deficiency of Bim in dendritic cells contributes to overactivation of lymphocytes and autoimmunity. Blood 2007; 109: 4360–4367.
7. Chen M, Huang L, Shabier Z, Wang J. Regulation of the Hexapin in dendritic cell subsets. Mol Immunol 2007; 44: 2558–2566.
8. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.
9. Strasser A, Cory S, Adams JM. Deepening the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667–3683.
10. Chen L, Wills SN, Wei A, Smith BJ, Fletcher JH, Hinds MG et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cancer 2008; 7: 393–403.
11. Liu X, Pan Z, Zhang L, Su Z, Wan J, Tian C et al. JAB1 accelerates mitochondrial apoptosis by interaction with proapoptotic BclGs. Cell Signal 2008; 20: 230–240.
12. Coulais L, Pellegrini M, Visvader JE, Lindemann GJ, Chen L, Adams JM et al. Bcl: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death Differ 2003; 10: 185–192.
14. Giam M, Mintern JD, Rautureau GJP, Hinds MG, Strasser A, Bouillet P. Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies. Cell Death and Disease 2012; 3: e-pub ahead of print 23 August 2012; doi:10.1038/cddis.2012.117.

15. Sacher M, Kim YG, Lavie A, Oh BH, Segev N. The TRAPP complex: insights into its architecture and function. Traffic 2008; 9: 2032–2042.

16. Yu S, Satoh A, Pypaert M, Mullen K, Hay JC, Ferro-Novick S. mBet3p is required for homotypic COPII vesicle tethering in mammalian cells. J Cell Biol 2006; 174: 359–368.

17. Montpetit A, Larose J, Bolly G, Langlois S, Trudel N, Sinnett D. Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia. Leukemia 2004; 18: 1499–1504.

18. Latil A, Bleche I, Cheva L, Laurendeau I, Berthon P, Cussenot O et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003; 9: 5477–5485.

19. Abdelhaleem M, Yi Q, Beimnet K, Hitzler J. A novel TEL-AML1 fusion transcript involving the pro-apoptotic gene BCL-G in pediatric precursor B acute lymphoblastic leukemia. Leukemia 2004; 18: 1499–1504.

20. Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELX) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res 2007; 9: R17.

21. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734–1741.

22. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17–27.

23. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7: 165–172.

24. Fuertes Marraco SA, Scott CL, Bouillet P, Ives A, Masina S, Vremec D et al. Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo. PLoS One 2011; 6: e20189.

25. Coultas L, Bouillet P, Loveland KL, Meachem S, Perlman H, Adams JM et al. Concomitant loss of proapoptotic BH3-only Bcl-2 antagonists Bik and Bim arrests spermatogenesis. Embo J 2005; 24: 3963–3973.

26. LeClerc FA, Sedgwick JD, Komer H. Gene targeting in C57BL/6 ES cells. Successful germ line transmission using recipient BALB/c blastocysts developmentally matured in vitro. Nucleic Acids Res 1997; 25: 917–918.

27. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 2000; 164: 2978–2986.

28. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17–27.

29. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7: 165–172.

Supplementary information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)